Found: 22
Select item for more details and to access through your institution.
Addressing the disparities: the approach to the African American patient with multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00961-0
- By:
- Publication type:
- Article
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
- Published in:
- Nature Medicine, 2015, v. 21, n. 8, p. 914, doi. 10.1038/nm.3910
- By:
- Publication type:
- Article
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
- Published in:
- British Journal of Haematology, 2016, v. 173, n. 6, p. 884, doi. 10.1111/bjh.14014
- By:
- Publication type:
- Article
Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
- Published in:
- Journal of Oncology Pharmacy Practice, 2010, v. 16, n. 1, p. 45, doi. 10.1177/1078155209105399
- By:
- Publication type:
- Article
Intravesicular Cidofovir in the Treatment of BK Virus-Associated Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A Clinical Perspective on Plasma Cell Leukemia: A Single-Center Experience.
- Published in:
- Cancers, 2024, v. 16, n. 11, p. 2149, doi. 10.3390/cancers16112149
- By:
- Publication type:
- Article
A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy in Patients With Multiple Myeloma.
- Published in:
- Integrative Cancer Therapies, 2014, v. 13, n. 5, p. 396, doi. 10.1177/1534735414534729
- By:
- Publication type:
- Article
Prospective Observational Study of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma: Microbiota Profiling and Cytokine Expression.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.704722
- By:
- Publication type:
- Article
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 1, p. 112, doi. 10.1093/neuonc/noaa183
- By:
- Publication type:
- Article
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e716, doi. 10.1016/j.clml.2022.03.013
- By:
- Publication type:
- Article
P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S160, doi. 10.1016/S2152-2650(21)02346-6
- By:
- Publication type:
- Article
P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
- By:
- Publication type:
- Article
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
- By:
- Publication type:
- Article
MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
- By:
- Publication type:
- Article
Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
- By:
- Publication type:
- Article
Eosinophilic Myocarditis in a Patient With Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00494-4
- By:
- Publication type:
- Article
Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 7, p. 1064, doi. 10.1002/cncr.29160
- By:
- Publication type:
- Article
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
- Published in:
- British Journal of Haematology, 2010, v. 150, n. 4, p. 428, doi. 10.1111/j.1365-2141.2010.08264.x
- By:
- Publication type:
- Article
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
- Published in:
- Ophthalmology & Therapy, 2020, v. 9, n. 4, p. 889, doi. 10.1007/s40123-020-00280-8
- By:
- Publication type:
- Article